Lead Product - BactelideTM for the Prevention of Topical AMR Infections

Sustained release topical designed to prevent AMR infections, with a first indication of significantly reducing pressure ulcer infections (later, labelling for this product will be expanded to include wound care, burn care, and possibly a role in diabetic ulcer care). 25% of all patients in bed for more than 7 days gets a bed sore. According to TMR analysis, in 2017, the sales volume of pressure ulcer treatment market alone was about US $4.54 billion. Due to the combined impact of aging population and antibiotic resistance, it is expected to grow to US $7.13 billion by 2026. The problem of pressure ulcer infection is very serious.

BactelideTM allows for the penetration and prolonged release of the phages deep within the wound bed where the target bacteria are present.